Skip to main content
SpringerLink
Log in

Calcium channel antagonists part IV: Side effects and contraindications drug interactions and combinations

  • Calcium Channel Modulation
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

With the correct selection of drug and patient, the calcium antagonists as a group can be remarkably effective at relatively low cost of serious side effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is given to patients with sinus or atrioventricular nodal depression from drugs or disease, or nifedipine to patients with aortic stenosis. The potential of a marked negative inotropic effect is usually offset by afterload reduction, especially in the case of nifedipine which actually has the most marked negative inotropic effect. Yet caution is required when even calcium antagonists, especially verapamil, are given to patients with myocardial failure unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as α-adrenergic blockers, β-adrenergic blockers, digoxin, quinidine, and disopyramide. The most marked interaction with digoxin is that with verapamil, which may raise digoxin levels by over 50%. Combination therapy of calcium antagonists with β-blockers is increasingly common, and is probably safest in the case of dihydropyridines. Other combinations being explored are those with angiotensinconverting enzyme inhibitors and diuretics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 1987; 10(Suppl 1):S121-S131.

    Google Scholar 

  2. Subramanian VB. Calcium Antagonists in Chronic Stable Angina Pectoris. Amsterdam: Excerpta Medica, 1983;97–116, 152–156, 217–229.

    Google Scholar 

  3. Lewis JG. Adverse reactions to calcium antagonists. Drugs 1983; 25:196–222.

    Google Scholar 

  4. Pepine CJ, Feldman RL, Hill JA, et al. Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. Am Heart J 1983; 106:1341–1347.

    Google Scholar 

  5. Dawson JR, Whitaker NHG, Sutton GC. Calcium antagonists in chronic stable angina. Comparison of verapamil and nifedipine. Br Heart J 1981; 46:508–512.

    Google Scholar 

  6. Midtbo K, Hals O, van der Meer J. Verpamil compared with nifedipine in the treatment of essential hypertension. J Cardiovasc Pharmacol 1982; 4(Suppl 3):363–368.

    Google Scholar 

  7. Sacks H, Kennelly BM. Verapamil in cardiac arrhythmias (letter). Br Med J 1972; 2:716.

    Google Scholar 

  8. Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH, eds. Calcium and the Heart. London: Academic Press, 1971;135–188.

    Google Scholar 

  9. Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. Br Med J 1980; 281:1462–1464.

    Google Scholar 

  10. Hugenholtz P, Verdouw PD, de Jong JW, et al. Nifedipine for angina and acute myocardial ischemia. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984;237–255.

    Google Scholar 

  11. Opie LH. Drugs and the Heart. London: Lancet, 1980;27–38.

    Google Scholar 

  12. Opie LH, Singh BN. Calcium channel antagonists (slow channel blockers). In: Opie LH, ed. Drugs for the Heart Second Expanded Edition. Orlando, Florida: Grune & Stratton, 1987;34–53

    Google Scholar 

  13. Norris RJ, Brooks SG. Pharmacokinetics of a sustained release formulation of verapamil in young and elderly adults. In: Raftery EB, ed. Verapamil SR. Once-daily Calcium Blockade in Angina and Hypertension. Langhorne: ADIS Press International, 1987;38–46.

    Google Scholar 

  14. Brodsky SJ, Cutler SS, Weiner DA, et al. Hepatotoxicity due to treatment with verapamil. Ann Intern Med 1981; 94:490–491.

    Google Scholar 

  15. Terry RW. Nifedipine therapy in angina pectoris: Evaluation of safety and side effects. Am Heart J 1982; 104:681–689.

    Google Scholar 

  16. Leisten L, Kuhlmann J, Ebner F. Side effects and pharmacodynamic interactions. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart-New York: Schattauer, 1986;270–314.

    Google Scholar 

  17. Prida XE, Gelman JS, Feldman RL, et al. Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm. J Am Coll Cardiol 1987; 9:412–419.

    Google Scholar 

  18. MacDonald JB. Muscle cramps during treatment with nifedipine (Letter). Br Med J 1982; 285:1744.

    Google Scholar 

  19. Jee LD, Opie LH. Nifedipine for hypertension and angina pectoris: Interactions during combination therapy. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984;339–346.

    Google Scholar 

  20. Jariwalla AG, Anderson EG. Production of ischaemic cardiac pain by nifedipine. Br Med J 1978; 1:1181–1182.

    Google Scholar 

  21. Sia STB, MacDonald PS, Triester B, et al. Aggravation of myocardial ischaemia by nifedipine. Med J Aust 1985; 142:48–50.

    Google Scholar 

  22. Bertel O, Conen D, Radu EW, et al. Nifedipine in hypertensive emergencies. Br Med J 1983; 286:19–21.

    Google Scholar 

  23. Opie LH. Fluid retention with nifedipine in antihypertensive therapy. Lancet 1986; ii:1456.

    Google Scholar 

  24. Marone C, Luisoli S, Bomio F, et al. Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine. Kidney Int 1985; 28:658–665.

    Google Scholar 

  25. Guazzi MD, De Cesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Hypertension 1984; 70:279–284.

    Google Scholar 

  26. Gillmer DJ, Kark P: Pulmonary oedema precipitated by nifedipine. Br Med J 1980; 280:1420–1421.

    Google Scholar 

  27. Diamond JR, Cheung JY, Fang LST. Nifedipine-induced renal dysfunction. Alterations in renal hemodynamics. Am J Med 1984; 77:905–909.

    Google Scholar 

  28. Krebs R. Adverse reactions with calcium antagonists. Hypertension 1983; 5(Suppl II):II-125-II-129.

    Google Scholar 

  29. Bhatnager SK, Amin MMA, Al-Yusuf AR. Diabetogenic effects of nifedipine. Br Med J 1984; 289:19.

    Google Scholar 

  30. Murphy MB, Scriven AJI, Dollery CT. Role of nifedipine in treatment of hypertension. Br Med J 1983; 287:257–259.

    Google Scholar 

  31. Myers MG, Leenen FHH, Burns R, et al. Nifedipine tablet vs hydralazine in patients with persisting hypertension who receive combined diuretic and beta-blocker therapy. Clin Pharmacol Ther 1986; 39:409–413.

    Google Scholar 

  32. Sowers JR, Mohanty PK. Comparison of calcium-entry blockers and diuretics in the treatment of hypertensive patients. Circulation 75 (Suppl V): V170–V173.

  33. Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina of effort: A multicenter trial. Am J Cardiol 1982; 49:567–572.

    Google Scholar 

  34. Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2:1129–1133.

    Google Scholar 

  35. Moser M. Calcium entry blockers for systematic hypertension. Am J Cardiol 1987; 59:15A-121A.

    Google Scholar 

  36. Petru MA, Crawford MH, Sorenson SG, et al. Short-and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease: A placebo-controlled, randomized, double-blind crossover study. Circulation 1983; 68:139–147.

    Google Scholar 

  37. Pool PE, Massie BM, Venkararaman K, et al. Diltiazem as monotherapy for systemic hypertensions: A multicenter, randomized, placebo-controlled trial. Am J Cardiol 1986; 57:212–217.

    Google Scholar 

  38. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73:316–324.

    Google Scholar 

  39. Steinberg JS, Katz RJ, Bren GB, et al. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987; 9:405–411.

    Google Scholar 

  40. Ishikawa T, Imamura T, Koiwaya Y, et al. Atrioventricular dissociation and sinus arrest induced by oral diltiazem. New Engl J Med 1983; 309:1124–1125.

    Google Scholar 

  41. Hung J, Lamb IH, Connolly SJ, et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: A double-blind, randomized, and placebo controlled study. Circulation 1983; 68:560–567.

    Google Scholar 

  42. Strauss WE, Egan T, McIntyre KM, et al. Combination therapy with diltiazem and propranolol: Precipitation of congestive heart failure. Clin Cardiol 1985; 8:363–366.

    Google Scholar 

  43. CMS Update. Annual review of yellow cards—1985. Br Med J 1986; 293:688.

    Google Scholar 

  44. Bardet J, Baudet M, Rigaud M, et al. Diltiazem, a new calcium antagonist, versus propranolol in treatment of spontaneous angina pectoris (abstr). Am J Cardiol 1979; 43:416.

    Google Scholar 

  45. Krikler DM, Curry VL. Torsade de pointes, an atypical ventricular tachycardia. Br Heart J 1976; 38:117–120.

    Google Scholar 

  46. Hanley SP, Hampton JR: Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J 1983; 4:889–893.

    Google Scholar 

  47. Ferlinz J, Citron PD. Hemodynamics and myocardial performance characteristics after verapamil use in congestive heart failure. Am J Cardiol 1983; 51:1339–1345.

    Google Scholar 

  48. Piepho RW, Culbertson VL, Rhodes RS. Drug interactions with the calcium-entry blockers. Circulation 1987: 75(Suppl V):V-181-V-194.

    Google Scholar 

  49. Jee LD, Opie LH. Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension. Br Med J 1983; 287:1514–1516.

    Google Scholar 

  50. Sluiter HE, Huysmans F Th M, Thien Th A, et al. The influence of alpha1-adrenergic blockade on the acute antihypertensive effect of nifedipine. Eur J Clin Pharmacol 1985; 29:263–267.

    Google Scholar 

  51. Elliott HL, Pasanisi F, Meredith PA, et al. Acute hypotensive response to nifedipine added to prazosin. Br Med J 1984; 288:238.

    Google Scholar 

  52. Pasanisi F, Elliot HL, Meredith PA, et al. Combined alpha-adrenoceptor antagonism and calcium channel blockade in normal subjects. Clin Pharmacol Ther 1984; 36:716–723.

    Google Scholar 

  53. Menasche S, Elkik F, Cocco G, et al. Synergistic antihypertensive effect of diltiazem combined with the alpha-adrenoceptor blocker alfuzosine (abstr). Ann NY Acad Sci (in press).

  54. Urthaler F, James TN. Experimental studies on the pathogenesis of asustole after verapamil in the dog. Am J Cardiol 1979; 44:651–656.

    Google Scholar 

  55. Kieval J, Kirstein EB, Kessler KM, et al. The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol. Circulation 1982; 65:653–659.

    Google Scholar 

  56. Packer M, Meller J, Medina N, et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982; 65:660–668.

    Google Scholar 

  57. Johnston DL, Lesoway R, Humen DP, et al. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in extertional angina pectoris: A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol 1985; 55:680–687.

    Google Scholar 

  58. Winniford MD, Fulton KL, Corbett JR. et al. Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: A randomized, double-blind crossover study. Am J Cardiol 1985; 55:281–285.

    Google Scholar 

  59. McLean AJ, Knight R, Harrison PM, et al. Clearance based oral drug interaction between verapamil and metoprolol and comparison with atenolol. Am J Cardiol 1985; 55:1628–1629.

    Google Scholar 

  60. Pfisterer M, Muller-Brand J, Burkart F. Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: Additional improvement of ischemia-induced left ventricular dysfunction. Am J Cardiol 1982; 49:1259–1266.

    Google Scholar 

  61. Millard RW, Lathrop DA, Grupp G, et al. Differential cardiovascular effects of calcium channel blocking agents: Potential mechanisms. Am J Cardiol 1982; 49:449–506.

    Google Scholar 

  62. Warltier DC, Zyvolski MG, Gross GJ, et al. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade. J Pharmacol Exp Ther 1984; 230:367–375.

    Google Scholar 

  63. Lynch P, Dargie H, Krikler S, et al. Objective assessment of antianginal and their combination. Br Med J 1980; 281:184–187.

    Google Scholar 

  64. Opie LH, Jee L, White D. Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. Am Heart J 1982; 104:606–612.

    Google Scholar 

  65. Brooks N, Cattell M, Pidgeon J, et al. Unpredictable response to nifedipine in severe cardiac failure (letter). Br Med J 1980; 281:1324.

    Google Scholar 

  66. Hamann SR, Kaltenborn KE, McAllister RG. Nifedipine-propranolol interaction: Dependence of cardiovascular effects on plasma drug concentrations. J Cardiovasc Pharmacol 1987;10:182–189.

    Google Scholar 

  67. Kleinbloesem CH, van Brummelen P, Sandberg THW, et al. Kinetic and haemodynamic interactions between nifedipine and propranolol in healthy subjects utilizing controlled rates of drug input. In: Kleinbloesem CH, ed. Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects. 's-Gravenhage: Drukkerij JH Pasmans BV, 1985;151–165.

    Google Scholar 

  68. Rosenkranz B, Ledermann H, Frolich JC. Interaction between nifedipine atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. J Cardiovasc Pharmacol 1986; 8:943–949.

    Google Scholar 

  69. Chaffman M, Brogden RN: Diltiazem: A review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29:387–454.

    Google Scholar 

  70. Tilmant PY, Lablanche JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983; 52:230–233.

    Google Scholar 

  71. Rocha P, Zannier D, Baron B, et al. Acute hemodynamic effects of intravenous nicardipine in patients treated chronically with propranolol for coronary artery disease. Am J Cardiol 1987; 59:775–781.

    Google Scholar 

  72. Culling W, Ruttley MSM, Sheridan DJ. Acute haemodynamic effects of delodipine during beta-blockade in patients with coronary artery disease. Br Heart J 1984; 52:431–434.

    Google Scholar 

  73. Duncker DJ, Hartog JM, Hugenholtz PG, et al. The effects of nisoldipine (Bay K 5552) on cardiovascular performance and regional blood flow in pentobarbital—anesthetized pigs with or without β-adrenoceptor blockade. Br J Pharmacol 1986; 88:9–18.

    Google Scholar 

  74. Kimura E, Kishida H: Treatment of variant angina with drugs: A survey of 11 cardiology institutes in Japan. Circulation 1981; 63:844–848.

    Google Scholar 

  75. Toyosaki N, Natsume T, Katsuki T, et al. Synergetic effects of nifedipine and diltiazem in effort angina pectoris (abstr). Circulation 1987; 76(Suppl IV):IV-92.

    Google Scholar 

  76. Lessem J, Bellinetto A. Interaction between digoxin and calcium antagonist (abstr). Am J Cardiol 1982; 49:1025.

    Google Scholar 

  77. Pedersen KE. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand 1985; (Suppl 697):12–40.

  78. Schwartz JB, Raizner A, Akers S. The effect of nifedipine on serum digoxin concentrations in patients. Am Heart J 1984; 107:669–673.

    Google Scholar 

  79. Elkayam U, Parikh K, Torkan B, et al. Effect of diltiazem on renal clearance and serum concentration of digoxin in patients with cardiac disease. Am J Cardiol 1985; 55:1393–1395.

    Google Scholar 

  80. Oyama Y, Fujii S, Kanda K, et al. Digoxin-diltiazem interaction. Am J Cardiol 1984; 53:1480–1481.

    Google Scholar 

  81. Kleinbloesem CH, van Brummelen P, Hillers J, et al. Interaction between digoxin and nifedipine at steady-state in patients with atrial fibrillation. In: Kleinbloesem CH, ed. Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects. 's-Gravenhage: Drukkerij JH Pasms BV, 1985;167–173.

    Google Scholar 

  82. Kirch W. Dihydropyridine derivatives, influence on digoxin disposition and haemodynamics (abstr). Ann NY Acad Sci (in press).

  83. Kirch W, Hutt HJ, Heidemann H, et al. Drug interactions with nitrendipine. J Cardiovasc Pharmacol 1984; 6(Suppl 7):S982-S985.

    Google Scholar 

  84. Cantelli I, Bracchetti D. Combined use of digoxin and nifedipine in the treatment of congestive heart failure. Pract Cardiol 1985; 11:75–87.

    Google Scholar 

  85. Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus varapamil. New Engl J Med 1985; 312:167–171.

    Google Scholar 

  86. Lee JT, Davy J-M, Kates RE. Evaluation of combined administration of verapamil and disopyramide in dogs. J Cardiovasc Pharmacol 1985; 7:501–507.

    Google Scholar 

  87. MacPhee GJA, McInnes GT, Thompson GG, et al. Verapamil potentiates carbamazepine neurotoxicity: A clinically important inhibitory interaction. Lancet 1986; i:700–703.

    Google Scholar 

  88. Bassan MM, Weiler-Ravell D, Shalev O. Comparison of the antianginal effectiveness of nifedipine, verapamil and isosorbide dinitrate in patients receiving propranolol: A double-blind study. Circulation 1983; 68:568–575.

    Google Scholar 

  89. Tolins M, Weir EK, Chesler E, et al. “Maximal” drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984; 3:1051–1057.

    Google Scholar 

  90. White HD, Polak JF, Wynne J, et al. Addition of nifedipine to maximal nitrate and beta-adrenoceptor blocker therapy in coronary artery disease. Am J Cardiol 1985; 55:1303–1307.

    Google Scholar 

  91. Singer DRJ, Markandu ND, Shore AC, et al. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 1987; 9:629–633.

    Google Scholar 

  92. Muller FB, Bolli P, Linder L, et al. Calcium antagonists and the second drug for hypertensive therapy. Am J Med 1986; 81(Suppl 6A):25–29.

    Google Scholar 

  93. MacGregor GA: Hypertension. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart: Schattauer, 1986; 231–258.

    Google Scholar 

  94. Daniels AR, Opie LH. Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone. Am J Cardiol 1986; 57:965–970.

    Google Scholar 

  95. Smith SR, Kendall MJ, Lobo J, et al. Ranitidine and cimetidine: Drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol 1987; 23:311–315.

    Google Scholar 

  96. Kirch W, Janisch HD, Heidmann H, et al. Effect of cimetidine and ranitidine on the pharmacokinetics and the antihypertensive action of nifedipine. Dtsch Med Wochenschr 1983; 108:1757–1761.

    Google Scholar 

  97. Lahiri A, Dasgupta P, Rodrigues EA, et al. Acute drug withdrawal in patients with stable angina on long-term treatment with verapamil. In: Raftery EB, ed. Verapamil SR. Langhorne: ADIS Press International, 1987;18–29.

    Google Scholar 

  98. Raftos J, Verapamil in the long-term treatment of angina pectoris. Med J Aust 1980; 2:78–80.

    Google Scholar 

  99. Stone PH. Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia. Therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1983; 59:101B-115B.

    Google Scholar 

  100. Gottlieb SO, Ouyang P, Achuff SC, et al. Acute nifedipine withdrawal: Consequences of preoperative and late cessation of therapy in patients with prior unstable angina. J Am Coll Cardiol 1984; 4:383–388.

    Google Scholar 

  101. Sorkin EM, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30:182–274.

    Google Scholar 

  102. Frishman W, Zawada ET, Smith K, et al. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild to moderate systemic hypertension. Am J Cardiol 1987; 59:615–623.

    Google Scholar 

  103. Schroeder JS, Walker SD, Skalland ML, et al. Absence of rebound from diltiazem therapy in Prinzmetal's variant angina. J Am Coll Cardiol 1985; 6:174–178.

    Google Scholar 

  104. Daniels AR, Opie LH. Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. Am J Cardiol 1987; 60:703–707.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Cape Town Medical School, Republic of South Africa

    Lionel H. Opie

Authors
  1. Lionel H. Opie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opie, L.H. Calcium channel antagonists part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drug Ther 2, 177–189 (1988). https://doi.org/10.1007/BF00051233

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051233

Key Words

Search

Navigation